Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
|Videos|March 9, 2015
Understanding ACOs & Emerging Delivery Market Influence to Drive Strategic Business Decisions
AJMC is proud to bring you an educational webinar that will tell how innovative data curation methods can provide well-informed, actionable business strategies for the evolving healthcare landscape.
Advertisement
AJMC is proud to bring you an educational webinar that will tell how innovative data curation methods can provide well-informed, actionable business strategies for the evolving healthcare landscape.
Advertisement
Related to this article
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Phase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
3
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5